[{"id":"0adf4251-1bfb-4026-9e02-9777cb6772ae","acronym":"Neo-POLEM","url":"https://clinicaltrials.gov/study/NCT06692959","created_at":"2025-02-26T13:54:47.835Z","updated_at":"2025-02-26T13:54:47.835Z","phase":"Phase 2","brief_title":"A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer","source_id_and_acronym":"NCT06692959 - Neo-POLEM","lead_sponsor":"University of Southampton","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD1-Vaxx"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-11-18"},{"id":"fc02363e-3ba6-4c72-af6a-3f50bff86e69","acronym":"IMPRINTER","url":"https://clinicaltrials.gov/study/NCT04432207","created_at":"2022-11-19T01:10:09.189Z","updated_at":"2024-07-02T16:35:22.181Z","phase":"Phase 1","brief_title":"A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04432207 - IMPRINTER","lead_sponsor":"Imugene Limited","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • PD1-Vaxx"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/30/2020","start_date":" 11/30/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-01-25"}]